>
Allovir Inc logo

ALVR - Allovir Inc Share Price

$19.87 -0.2  -0.8%

Last Trade - 18/06/21

Sector
Healthcare
Size
Mid Cap
Market Cap £936.8m
Enterprise Value £692.8m
Revenue £n/a
Position in Universe 2654th / 6927
Bullish
Bearish
Unlock ALVR Revenue
Momentum
Relative Strength (%)
1m -7.32%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -59.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 1.14 0.17 0.000 -100.0%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2021, AllovirInc revenues was not reported. Net loss increased from$9.3M to $30.9M. Higher net loss reflects Research anddevelopment increase from $6.6M to $17.1M (expense),Stock-based Compensation in SGA increase from $432K to$4.8M (expense), General and administrative increase from$2.6M to $5.7M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ALVR Revenue Unlock ALVR Revenue

Net Income

ALVR Net Income Unlock ALVR Revenue

Normalised EPS

ALVR Normalised EPS Unlock ALVR Revenue

PE Ratio Range

ALVR PE Ratio Range Unlock ALVR Revenue

Dividend Yield Range

ALVR Dividend Yield Range Unlock ALVR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ALVR EPS Forecasts Unlock ALVR Revenue
Profile Summary

AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. The Company’s product pipeline includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi-VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV) adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus six (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). LVR109 is an allogeneic VST therapy that targets severe acute respiratory syndrome coronavirus two (SARS-CoV-2).

Directors
Last Annual December 31st, 2020
Last Interim March 31st, 2021
No. of Shareholders: 110
No. of Employees: 53
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 65,106,873
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ALVR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ALVR
Upcoming Events for ALVR
Tuesday 31st August, 2021 Estimate
Q2 2021 Allovir Inc Earnings Release
Monday 8th November, 2021 Estimate
Q3 2021 Allovir Inc Earnings Release
Frequently Asked Questions for Allovir Inc
What is the Allovir Inc share price?

As of 18/06/21, shares in Allovir Inc are trading at $19.87, giving the company a market capitalisation of £936.8m. This share price information is delayed by 15 minutes.

How has the Allovir Inc share price performed this year?

Shares in Allovir Inc are currently trading at $19.87 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Allovir Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Allovir Inc?

There are no analysts currently covering Allovir Inc.

When will Allovir Inc next release its financial results?

Allovir Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Allovir Inc dividend yield?

Allovir Inc does not currently pay a dividend.

Does Allovir Inc pay a dividend?

Allovir Inc does not currently pay a dividend.

When does Allovir Inc next pay dividends?

Allovir Inc does not currently pay a dividend.

How do I buy Allovir Inc shares?

To buy shares in Allovir Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Allovir Inc?

Shares in Allovir Inc are currently trading at $19.87, giving the company a market capitalisation of £936.8m.

Where are Allovir Inc shares listed? Where are Allovir Inc shares listed?

Here are the trading details for Allovir Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ALVR
What kind of share is Allovir Inc?

Based on an overall assessment of its quality, value and momentum, Allovir Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Allovir Inc share price forecast 2021?

Shares in Allovir Inc are currently priced at $19.87. At that level they are trading at 0.147% discount to the analyst consensus target price of 0.00.

Analysts covering Allovir Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.953 for the next financial year.

How can I tell whether the Allovir Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Allovir Inc. Over the past six months, the relative strength of its shares against the market has been -51.38%. At the current price of $19.87, shares in Allovir Inc are trading at -35.23% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Allovir Inc PE Ratio?

We were not able to find PE ratio data for Allovir Inc.

Who are the key directors of Allovir Inc?

Allovir Inc's management team is headed by:

David Hallal - CHM
Vikas Sinha - PRE
Ann Leen - CFD
Agustin Melian - OTH
Jeroen van Beek - OTH
Brett Hagen - CAO
Ercem Atillasoy - OTH
Edward Miller - GCN
Jeffrey Bornstein - IND
Diana Brainard - CEO
Malcolm Brenner - IND
Ansbert Gadicke - IND
Morana Jovan-Embiricos - IND
Juan Vera - DRC
Who are the major shareholders of Allovir Inc?

Here are the top five shareholders of Allovir Inc based on the size of their shareholding:

ElevateBio LLC Corporation
Percentage owned: 20.61% (13.4m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 10.69% (6.96m shares)
Wilson (John Robert) Individual Investor
Percentage owned: 8.54% (5.56m shares)
Globeways Holdings II Ltd Corporation
Percentage owned: 7.62% (4.96m shares)
Hallal (David L) Individual Investor
Percentage owned: 6.06% (3.94m shares)
Similar to ALVR
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.